Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 0.69 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.68 |
| ▸ | CDK2 | P24941 | 1/20 | 0.68 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | DNM1L | O00429 | 1/20 | 0.49 |
| ▸ | FABP3 | P05413 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830121 | 0.89 | CHEK1 (0.61) | CHEK1CCNE1CDK2PLA2G10NPC1 | |
| SCHEMBL1829212 | 0.88 | CHEK1 (0.61) | CHEK1CCNE1CDK2PLA2G10NPC1 | |
| SCHEMBL1829073 | 0.86 | CHEK1 (0.67) | CHEK1CCNE1CDK2NPC1RAB9A | |
| SCHEMBL14328467 | 0.83 | CHEK1 (0.85) | CHEK1CCNE1CDK2PLA2G10 | |
| SCHEMBL13617382 | 0.82 | PLA2G10 (0.81) | CHEK1CCNE1CDK2PLA2G10NPC1 | |
| SCHEMBL14206517 | 0.82 | CHEK1 (1.00) | CHEK1CCNE1CDK2PLA2G10 | |
| SCHEMBL16365870 | 0.82 | CHEK1 (0.65) | CHEK1CCNE1CDK2PLA2G10NPC1 | |
| SCHEMBL14206798 | 0.81 | CHEK1 (1.00) | CHEK1CCNE1CDK2 | |
| SCHEMBL14206518 | 0.81 | CHEK1 (1.00) | CHEK1CCNE1CDK2PLA2G10NPC1 | |
| SCHEMBL1830550 | 0.81 | PIM1 (0.67) | CHEK1CCNE1CDK2PLA2G10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163739-B2 | 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-24 | — | — | US | claimed |
| EP-2240457-B1 | NOVEL 2-ARYL-THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AG (DE) | 2011-05-11 | — | — | EP | claimed |
| US-20090163486-A1 | Novel 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-25 | — | — | US | claimed |
| EP-2070916-A1 | 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | claimed |
| US-8163739-B2 | 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-24 | — | — | US | disclosed |
| US-8163739-B2 | 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-24 | — | — | US | disclosed |
| US-8163739-B2 | 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-24 | — | — | US | disclosed |
| EP-2240457-B1 | NOVEL 2-ARYL-THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| EP-2240457-A1 | NOVEL 2-ARYL-THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-20 | — | — | EP | disclosed |
| US-20090163486-A1 | Novel 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009074247-A1 | NOVEL 2-ARYL-THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070916-A1 | 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163486-A1 | Novel 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | CNR2, ABAT, TPMT | CHEK1 3993/4885CCNE1 2572/4885CDK2 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.